HAMILTON THORNE LAUNCHES LYKOS™ LASER SYSTEM FOR FERTILITY AND CLINICAL MARKETS AT ESHRE 2011
LYKOS’ Innovative Design Includes Laser and RED-i Target Built Directly Into Objective for Easy Integration with Standard Microscopes and Research Processes
BEVERLY, MA and TORONTO, Ontario – June 27, 2011 - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems for the regenerative medicine, fertility and stem cell research markets, today announced the launch of its ground-breaking LYKOS™ laser system for the clinical and fertility markets. LYKOS™ will be unveiled during the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) taking place in Stockholm, Sweden, July 3-6, 2011.
The LYKOS™ is a significant advance in integrated laser optics, providing additional functionality, improved optics, increased resolution and compatibility with all major microscope models. The elegant and sleek new design of the LYKOS™ is engineered to have the laser and RED-i target locator built directly inside the objective, saving researchers from tedious alignment procedures. The improved working distance will be a significant advantage in the daily workflow. The laser also features enhanced UV transmission/fluorescence, which is compatible with many fluorescing stains. The LYKOS™ also offers additional benefits for cutting-edge clinical processes such as trophectoderm biopsy, blastomere biopsy, pre-implantation genetic diagnosis (PGD), and laser-assisted hatching.
“The new LYKOS™ represents a quantum leap in laser technology with its compact design, long working distance and excellent optics,” said Meg Spencer, Chief Executive Officer of Hamilton Thorne Ltd. “The image quality and increased resolution provides our customers with immediate benefits, especially in IVF clinics. The LYKOS™ is already generating strong customer interest with a number of units pre-sold prior to the launch. Further, with its enhanced capabilities, researchers can perform advanced cellular research that should lead to improved scientific processes. Current research using laser technology is unmasking potential therapeutic treatments for today’s most devastating diseases.”
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne provides novel solutions for Life Science that reduce cost, increase productivity as much as ten-fold, and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. The Company’s new LYKOS™, Staccato™ and Stiletto™ laser systems offer significant scientific advantages in the fields of developmental biology, cancer research and advanced cell biology. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and procedures. Each member of Hamilton Thorne’s family of products serves a different research purpose. By simply turning the microscope turret, researchers can have a new world of scientific capabilities at their fingertips.
Hamilton Thorne’s growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, McGill University, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.